Antibody-based candidate therapeutics against HIV-1: Implications for virus eradication and vaccine design

Expert Opinion on Biological Therapy

Volumn 13, Issue 5, 2013, Pages 657-671

  Chen, Weizao ^a   Ying, Tianlei ^a   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Broadly neutralizing monoclonal antibodies; Eradication; HIV 1; Prophylactics; Therapeutics; Vaccines

Indexed keywords

ALVIRCEPT SUDOTOX; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; IBALIZUMAB; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 3BNC117; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY A12; MONOCLONAL ANTIBODY B12; MONOCLONAL ANTIBODY J3; MONOCLONAL ANTIBODY M36; MONOCLONAL ANTIBODY NIH45; MONOCLONAL ANTIBODY NIH46; MONOCLONAL ANTIBODY PG16; MONOCLONAL ANTIBODY PG9; MONOCLONAL ANTIBODY PGT 125; MONOCLONAL ANTIBODY PGT 126; MONOCLONAL ANTIBODY PGT 127; MONOCLONAL ANTIBODY PGT 128; MONOCLONAL ANTIBODY VRC01; MONOCLONAL ANTIBODY VRC02; MONOCLONAL ANTIBODY VRC03; MONOCLONAL ANTIBODY VRCPG04; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ENVELOPE PROTEIN; VORINOSTAT;

ANTIBODY RESPONSE; CANCER THERAPY; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; COMPLEMENTARITY DETERMINING REGION; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DRUG DESIGN; ERADICATION THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; NEOPLASM; PROPHYLAXIS; REVIEW; SINGLE DRUG DOSE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; VIRUS ATTENUATION; VIRUS EXPRESSION; VIRUS REPLICATION; VIRUS RESISTANCE;

AIDS VACCINES; DISEASE RESERVOIRS; DRUG DESIGN; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; VACCINES, SYNTHETIC;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84876059306     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.761969     Document Type: Review

References (114)

1. Smith MZ, Wightman F, Lewin SR. HIV reservoirs and strategies for eradication. Curr HIV AIDS Rep 2012;9:5-15
2. Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 2012;26:1261-8
3. Deeks SG, Autran B, Berkhout B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012;12:607-14
4. Palmer S, Josefsson L, Coffin JM. HIV reservoirs and the possibility of a cure for HIV infection. J Intern Med 2011;270:550-60
5. Barbaro G, Scozzafava A, Mastrolorenzo A, et al. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005;11:1805-43
6. Rusconi S, Scozzafava A, Mastrolorenzo A, et al. An update in the development of HIV entry inhibitors. Curr Top Med Chem 2007;7:1273-89
7. Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends-is a paradigm change coming soon? Methods Mol Biol 2009;525:1-27, xiii
8. Dimitrov DS. Therapeutic proteins. Methods Mol Biol 2012;899:1-26
9. Chen W, Dimitrov DS. Monoclonal antibody-based candidate therapeutics against HIV type 1. AIDS Res Hum Retroviruses 2012;28:425-34
10. Gong R, Chen W, Dimitrov DS. Candidate antibody-based therapeutics against HIV-1. BioDrugs 2012;26:143-62
11. Ada GL. Human vaccines. Dev Biol Stand 1994;82:181-8
12. Adkins JC, Wagstaff AJ. Recombinant hepatitis B vaccine: a review of its immunogenicity and protective efficacy against hepatitis B. BioDrugs 1998;10:137-58
13. Li G, Chen W, Yan W, et al. Comparison of immune responses against foot-and-mouth disease virus induced by fusion proteins using the swine IgG heavy chain constant region or beta-galactosidase as a carrier of immunogenic epitopes. Virology 2004;328:274-81
14. Bonsignori M, Alam SM, Liao HX, et al. HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol 2012;20:532-9
15. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-20
16. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360:692-8
17. Chen W, Dimitrov DS. Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors. Curr Opin HIV AIDS 2009;4:112-17
18. Burton DR, Poignard P, Stanfield RL, et al. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012;337:183-6
19. Roben P, Moore JP, Thali M, et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994;68:4821-8
20. Buchacher A, Predl R, Strutzenberger K, et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994;10:359-69
21. Purtscher M, Trkola A, Gruber G, et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994;10:1651-8
22. Stiegler G, Kunert R, Purtscher M, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001;17:1757-65
23. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326:285-9
24. Wu X, Yang ZY, Li Y, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010;329:856-61
25. Scheid JF, Mouquet H, Ueberheide B, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011;333:1633-7
26. Diskin R, Scheid JF, Marcovecchio PM, et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 2011;334:1289-93
27. Wu X, Zhou T, Zhu J, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011;333:1593-602
28. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011;477:466-70
29. Huang J, Ofek G, Laub L, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012;491:406-12
30. Zhu Z, Qin HR, Chen W, et al. Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J Virol 2011;85:11401-8
31. Abela IA, Berlinger L, Schanz M, et al. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog 2012;8:e1002634
32. Dimitrov DS, Willey RL, Sato H, et al. Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 1993;67:2182-90
33. Chen W, Zhu Z, Feng Y, et al. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci USA 2008;105:17121-6
34. Forsman A, Beirnaert E, Aasa-Chapman MM, et al. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol 2008;82:12069-81
35. McCoy LE, Quigley AF, Strokappe NM, et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J Exp Med 2012;209:1091-103
36. Sun M, Pace C, Yu J, et al. Rational design of a novel bispecific HIV-1-neutralizing antibody, Ibalizumabm36 [abstracts:436]. 18th Conference on Retroviruses and Opportunistic Infections; 2012
37. Pegu A, Yang Z, Chen X, et al. VRC01 provides sterilizing protection to non human primates from mucosal SHIV challenges. J Immunol 2011;186:155.11
38. Zhang C, Zheng J, Chen W, et al. Protective immunity: eAd inhibit in vivo HIV infection in humanized mice and can be expressed by lentiviral vectors to reprogam cells to secrete broadly neutralizing anti-HIV antibodies [abstracts:379]. 18th Conference on Retroviruses and Opportunistic Infections; 2011
39. Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012
40. Balazs AB, Chen J, Hong CM, et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012;481:81-4
41. Gray ES, Madiga MC, Moore PL, et al. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol 2009;83:11265-74
42. Shen X, Parks RJ, Montefiori DC, et al. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 2009;83:3617-25
43. Zhang MY, Wang Y, Mankowski MK, et al. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen. Vaccine 2009;27:857-63
44. Joyce JG, Hurni WM, Bogusky MJ, et al. Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J Biol Chem 2002;277:45811-20
45. Zhou M, Kostoula I, Brill B, et al. Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice. Vaccine 2012;30:1911-16
46. Dennison SM, Sutherland LL, Jaeger FH, et al. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS One 2011;6:e27824
47. Cardoso RM, Zwick MB, Stanfield RL, et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005;22:163-73
48. Ofek G, Tang M, Sambor A, et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004;78:10724-37
49. Ofek G, Guenaga FJ, Schief WR, et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci USA 2010;107:17880-7
50. Correia BE, Ban YE, Holmes MA, et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 2010;18:1116-26
51. Guenaga J, Dosenovic P, Ofek G, et al. Heterologous epitope-scaffold prime: boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS One 2011;6:e16074
52. Burton DR. Scaffolding to build a rational vaccine design strategy. Proc Natl Acad Sci USA 2010;107:17859-60
53. Haynes BF, Fleming J, St Clair EW, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005;308:1906-8
54. Sanchez-Martinez S, Lorizate M, Katinger H, et al. Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res Hum Retroviruses 2006;22:998-1006
55. Xiao XD, Chen WZ, Feng Y, et al. Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. Viruses Basel 2009;1:802-17
56. Alam SM, Morelli M, Dennison SM, et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 2009;106:20234-9
57. Ofek G, McKee K, Yang Y, et al. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol 2010;84:2955-62
58. Kim M, Sun ZY, Rand KD, et al. Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat Struct Mol Biol 2011;18:1235-43
59. Matyas GR, Wieczorek L, Beck Z, et al. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS 2009;23:2069-77
60. Xiang SH, Kwong PD, Gupta R, et al. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 2002;76:9888-99
61. Martin G, Burke B, Thai R, et al. Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic. J Biol Chem 2011;286:21706-16
62. Fouts TR, Tuskan R, Godfrey K, et al. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J Virol 2000;74:11427-36
63. DeVico A, Fouts T, Lewis GK, et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci USA 2007;104:17477-82
64. Decker JM, Bibollet-Ruche F, Wei X, et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005;201:1407-19
65. Labrijn AF, Poignard P, Raja A, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003;77:10557-65
66. Zhou T, Xu L, Dey B, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007;445:732-7
67. Dey B, Svehla K, Xu L, et al. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog 2009;5:e1000445
68. Dey B, Pancera M, Svehla K, et al. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J Virol 2007;81:5579-93
69. Feng Y, McKee K, Tran K, et al. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site. J Biol Chem 2012;287:5673-86
70. Chen W, Feng Y, Wang Y, et al. Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies. Biochem Biophys Res Commun 2012;425:931-7
71. Tran EE, Borgnia MJ, Kuybeda O, et al. Structural mechanism of Trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog 2012;8:e1002797
72. Meyerson JR, Tran EEH, Kuybeda O, et al. Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives. Proc Natl Acad Sci USA In press
73. Chen W, Zhu Z, Liao H, et al. Cross-reactive human IgM-derived monoclonal antibodies that bind to HIV-1 envelope glycoproteins. Viruses 2010;2:547-65
74. Phogat S, Wyatt R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr Pharm Des 2007;13:213-27
75. Nkolola JP, Peng H, Settembre EC, et al. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J Virol 2010;84:3270-9
76. Kovacs JM, Nkolola JP, Peng H, et al. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci USA 2012;109:12111-16
77. Yang L, Song Y, Li X, et al. HIV-1 Virus-Like Particles Produced by Stably Transfected Drosophila S2 Cells: a Desirable Vaccine Component. J Virol 2012;86:7662-76
78. Tong T, Crooks ET, Osawa K, et al. HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. J Virol 2012;86:3574-87
79. Xiao X, Chen W, Feng Y, et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 2009;390:404-9
80. Ota T, Doyle-Cooper C, Cooper AB, et al. Anti-HIV B Cell Lines as Candidate Vaccine Biosensors. J Immunol 2012;189:4816-24
81. Hoot SJ, McGuire A, Cohen KW, et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog In press
82. Chen W, Streaker ED, Russ DE, et al. Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: implications for mechanisms of immune evasion and design of vaccine immunogens. Biochem Biophys Res Commun 2012;417:1164-9
83. Xiao X, Feng Y, Chen W, et al. Guiding the immune system through complex maturation pathways: a novel multi-immunogen approach for elicitation of broadly neutralizing antibodies. Retrovirology 2009;6:P35
84. Dimitrov DS. Therapeutic antibodies, vaccines and antibodyomes. MAbs 2010;2:347-56
85. Haynes BF, Kelsoe G, Harrison SC, et al. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012;30:423-33
86. Ma BJ, Alam SM, Go EP, et al. Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog 2011;7:e1002200
87. Abbas W, Herbein G. Molecular understanding of HIV-1 Latency. Adv Virol 2012;2012:574967
88. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387:183-8
89. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-17
90. Zagury D, Bernard J, Leonard R, et al. Long-term cultures of HTLV-III-infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science 1986;231:850-3
91. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987;326:711-13
92. Chun TW, Engel D, Mizell SB, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999;5:651-5
93. Scripture-Adams DD, Brooks DG, Korin YD, et al. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 2002;76:13077-82
94. Scheller C, Ullrich A, McPherson K, et al. CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. J Biol Chem 2004;279:21897-902
95. Hezareh M. Prostratin as a new therapeutic agent targeting HIV viral reservoirs. Drug News Perspect 2005;18:496-500
96. Dechristopher BA, Loy BA, Marsden MD, et al. Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem 2012;4:705-10
97. Ylisastigui L, Archin NM, Lehrman G, et al. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004;18:1101-8
98. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005;366:549-55
99. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487:482-5
100. Yang HC, Shen L, Siliciano RF, et al. Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. Proc Natl Acad Sci USA 2009;106:6321-6
101. Micheva-Viteva S, Kobayashi Y, Edelstein LC, et al. High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor. J Biol Chem 2011;286:21083-91
102. Huang J, Wang F, Argyris E, et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 2007;13:1241-7
103. Moldt B, Shibata-Koyama M, Rakasz EG, et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 2012;86:6189-96
104. Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med 2012;14:405-15
105. Kennedy PE, Bera TK, Wang QC, et al. Anti-HIV-1 immunotoxin 3B3(Fv)- PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques. J Leukoc Biol 2006;80:1175-82
106. Berger EA, Pastan I. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog 2010;6:e1000803
107. Davey RT Jr, Boenning CM, Herpin BR, et al. Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect Dis 1994;170:1180-8
108. Wu X, Wang C, O'Dell S, et al. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol 2012;86:5844-56
109. Steckbeck JD, Sun C, Sturgeon TJ, et al. Topology of the C-terminal tail of HIV-1 gp41: differential exposure of the Kennedy epitope on cell and viral membranes. PLoS ONE 2010;5:e15261
110. Chun TW, Nickle DC, Justement JS, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008;197:714-20
111. Chen W, Feng Y, Gong R, et al. Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens. J Virol 2011;85:9395-405
112. Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Oncol Clin North Am 2012;26:447-81.vii
113. Duvic M, Talpur R. Optimizing denileukin diftitox (Ontak) therapy. Future Oncol 2008;4:457-69
114. Stasi R, Evangelista ML, Buccisano F, et al. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev 2008;34:49-60